

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3309)

PROFIT WARNING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The Board wishes to inform the shareholders (the “**Shareholders**”) of the Company and prospective investors of the shares of the Company that the consolidated profit after tax of the Group for the six months ended 30 June 2018 would decrease by 50% to 60%, as compared to the same for the six months ended 30 June 2017, even though the amount of the consolidated revenue of the Group is expected to increase by more than 30% during the same period. The decrease in the amount of the consolidated profit after tax was primarily due to the following reasons:

- (1) additional operating costs of the Group’s eye hospital in Beijing which commenced business operations in January 2018 and was in the initial investment stage during the period; and
- (2) an exchange loss incurred by the Group as a result of the continuous depreciation of Renminbi against Hong Kong dollars in relation to certain bank deposits maintained by the Group in Hong Kong and denominated in Renminbi, and such loss cannot be fully compensated by the interest income generated from the bank deposits which have been subsequently converted into Hong Kong dollars during mid of July 2018.

The Board is in the process of finalising the unaudited consolidated interim results of the Group for the six months ended 30 June 2018. Information contained in this announcement is based on the preliminary information available to the Board and the unaudited consolidated management accounts of the Group and has yet to be reviewed or confirmed by the auditors of the Company and the audit committee of the Board and may be different from the unaudited

consolidated interim results of the Group for the six months ended 30 June 2018. The results announcement of the Company for the six months ended 30 June 2018 will be published by the Company by the end of August 2018 in full compliance with the requirements under the Listing Rules.

Shareholders and prospective investors of the shares of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu

Chairman and Chief Executive Officer and Executive Director

Hong Kong, 17 August 2018

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and five independent non-executive Directors, namely Dr. LAU Johnson Yiu-Nam, Dr. LI Kwok Tung Donald, Mr. MA Chiu Cheung Andrew, Mr. CHAN Chi Leong and Ms. BENTLEY Annie Liang.